Illumina Inc. (ILMN) shares are soaring 5.04% in pre-market trading on Wednesday, as the company unveils groundbreaking technologies and receives recognition for its potential in AI-driven healthcare innovation. The genomics giant is making waves with its new Constellation technology and 5-Base Solution, both of which promise to revolutionize genetic research and analysis.

Illumina's Constellation mapped read technology has shown impressive results in a GeneDx clinical study for rare disease genomics. The technology reportedly outperforms traditional methods in accuracy, speed, and ease of use when identifying difficult-to-map genomic variants. This breakthrough could significantly advance the field of rare disease research and diagnostics. Additionally, Illumina has launched its 5-Base Solution, enabling simultaneous genomic and epigenomic analysis from a single sample, which could streamline workflows and reduce costs in various research areas including rare diseases, cancer, and precision medicine.

Further bolstering Illumina's stock performance is industry expert Cathie Wood's recent comments highlighting healthcare as "the most profound application of AI." Wood specifically mentioned Illumina as a key player in creating faster, more cost-effective DNA sequencing tools. This endorsement from a prominent investor underscores the potential for Illumina's technologies to play a crucial role in the convergence of AI and genomics, positioning the company at the forefront of what Wood calls an "underexplored AI opportunity" in healthcare. As Illumina continues to innovate and expand its technological capabilities, investors appear optimistic about the company's future growth prospects in the rapidly evolving field of AI-driven genomic research and healthcare solutions.